A Study to Assess the Efficacy and Safety of BIVV009 (Sutimlimab) in Participants With Primary Cold Agglutinin Disease Who Have a Recent History of Blood Transfusion (Cardinal Study)
Clinical trial NCT03347396 · COMPLETED
Trial details
- NCT number
- NCT03347396
- Sponsor
- Bioverativ, a Sanofi company
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-03-05
- Primary completion
- 2021-10-05
- Enrollment
- 24
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.